In recent years, the application of endocrine, targeted therapy drugs represented by PARP1 inhibitors and neoadjuvant therapy has made traditional diagnostic indicators unsuitable for predicting the prognosis of BC patients. This evidence concerns the gene PARP1 and breast cancer.